Featured Video Play Icon

Three successful days for TIEFENBACHER GROUP at CPhI 2021 – thanks for visiting us in Milano!

With over 1,300 exhibitors and more than 20,000 attendees the world`s leading pharma event CPhI has just come to an end. It was three very successful days for TIEFENBACHER GROUP…

Read More

Featured Video Play Icon

At TIEFENBACHER GROUP giving back to society is important to us: New school building in India

As a value-driven healthcare company, dedicated to improve the life of patients worldwide, we believe that it´s our responsibility to care about the environment and society –…

Read More

Reach out to TIEFENBACHER GROUP at CPhI in Milan from 9-11th Nov and discover our latest ideas to make pharmaceuticals more affordable, more available and better than before!

“Nothing can replace meeting each other in person!” says Oliver Schrader, Managing Director of Tiefenbacher Group. After nearly two years of mainly digital work, we are very excited to be back on the…

Read More

New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the antihistamine Bilastine

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level or nationality. That´s why we are excited…

Read More

New agreement expands collaboration between OnDosis and TIEFENBACHER GROUP

Swedish Life science company OnDosis and German B2B pharmaceutical company TIEFENBACHER GROUP initiate four new innovative development projects targeting ADHD, rare diseases, and transplantation…

Read More

Spreading of Post COVID-19 Disease „Black Fungus“ in India – TIEFENBACHER GROUP supports with Posaconazole Tablets

Black Fungus (Mucormycosis) is dramatically spreading in India connected to the extensive 2nd COVID-19 wave. The highly life-threatening disease usually occurs as a rare disease in immunocompromised…

Read More

TIEFENBACHER GROUP announces global launch of TIEFENBACHER MEDICAL DEVICES

After more than five years in operation, TIEFENBACHER GROUP will transfer its medical device business into a new stand-alone company: TIEFENBACHER MEDICAL DEVICES. The launch follows TIEFENBACHER…

Read More

TIEFENBACHER PHARMACEUTICALS announces global launch of Teriflunomide making multiple sclerosis therapy more affordable and better available worldwide

TIEFENBACHER PHARMACEUTICALS, part of TIEFENBACHER GROUP, has successfully developed a global dossier for a generic version of Teriflunomide 7 mg and 14 mg film-coated tablets.   Teriflunomide is an…

Read More

AET Pharma US Inc. Announces Successful approval of generic Posaconazole by the Food and Drug Administration (FDA)

On 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval of the Abbreviated New Drug Application (ANDA) for Posaconazole 100 mg Delayed-Release Tablets. This is…

Read More

TIEFENBACHER PHARMACEUTICALS Announces Global Launch Of Rivaroxaban

TIEFENBACHER PHARMACEUTICALS, part of Tiefenbacher Group, is pleased to announce the availability of a registration dossier for the generic of Rivaroxaban 2.5 mg, 10 mg, 15 mg and 20 mg film-coated…

Read More

International Brand Relaunch of TIEFENBACHER GROUP

“We are very excited to launch our new AET website, representing the pharmaceutical FDF business of TIEFENBACHER GROUP. It is an important milestone within the international brand relaunch of our…

Read More

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’…

Read More